Generation of High-Titer Pseudotyped Lentiviral Vectors

  • Shuang Hu
  • Mingjie Li
  • Ramesh AkkinaEmail author
Part of the Methods in Molecular Biology book series (MIMB, volume 1937)


Lentiviral vectors (LVs) are widely used in gene transfer protocols due to many advantages that include stable gene expression, higher transgene payloads, and, importantly, the ability to pseudotype the vectors with a diverse number of heterologous viral envelopes with broad or restricted cell tropism depending on the need. The pseudotyping process also allows for incorporation of specific antibodies/ligands to engineer LVs. These features greatly facilitate customization of lentiviral vectors for cell/tissue specific gene delivery. The VSV-G protein containing envelope remains the most widely used among the viral glycoproteins used for LV pseudotyping due to its versatile host range and stability. However, many other viral envelopes are being identified for special applications of LVs. Here we describe the methodology to generate pseudotyped LVs using a four-plasmid transient transfection system focusing on aspects to generate high-titer vector stocks.

Key words

Lentiviral vector Viral vector pseudotyping Vector pseudotyping with VSV-G Vector production and concentration Vector titration 



Work reported here was supported by NIH grants to RA. We would like to thank Lauren Kinner-Bibeau for assistance in manuscript preparation.


  1. 1.
    McCarron A, Donnelley M, McIntyre C et al (2016) Challenges of up-scaling lentivirus production and processing. J Biotechnol 240:23–30CrossRefGoogle Scholar
  2. 2.
    Joglekar AV, Sandoval S (2017) Pseudotyped lentiviral vectors: one vector, many guises. Hum Gene Ther Methods 28:291–301CrossRefGoogle Scholar
  3. 3.
    Merten OW, Hebben M, Bovolenta C (2016) Production of lentiviral vectors. Mol Ther Methods Clin Dev 3:16017CrossRefGoogle Scholar
  4. 4.
    Segura MM, Mangion M, Gaillet B et al (2013) New developments in lentiviral vector design, production and purification. Expert Opin Biol Ther 13:987–1011CrossRefGoogle Scholar
  5. 5.
    Cronin J, Zhang XY, Reiser J (2005) Altering the tropism of lentiviral vectors through pseudotyping. Curr Gene Ther 5:387–398CrossRefGoogle Scholar
  6. 6.
    Burns JC, Friedmann T, Driever W et al (1993) Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc Natl Acad Sci U S A 90:8033–8037CrossRefGoogle Scholar
  7. 7.
    Finkelshtein D, Werman A, Novick D et al (2013) LDL receptor and its family members serve as the cellular receptors for vesicular stomatitis virus. Proc Natl Acad Sci U S A 110:7306–7311CrossRefGoogle Scholar
  8. 8.
    Naldini L, Blomer U, Gallay P et al (1996) In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272:263–267CrossRefGoogle Scholar
  9. 9.
    Zufferey R, Dull T, Mandel RJ et al (1998) Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol 72:9873–9880PubMedPubMedCentralGoogle Scholar
  10. 10.
    Akkina RK, Walton RM, Chen ML et al (1996) High-efficiency gene transfer into CD34+ cells with a human immunodeficiency virus type 1-based retroviral vector pseudotyped with vesicular stomatitis virus envelope glycoprotein G. J Virol 70:2581–2585PubMedPubMedCentralGoogle Scholar
  11. 11.
    Li M, Husic N, Lin Y et al (2010) Optimal promoter usage for lentiviral vector-mediated transduction of cultured central nervous system cells. J Neurosci Methods 189:56–64CrossRefGoogle Scholar
  12. 12.
    Kobayashi K, Inoue KI, Tanabe S et al (2017) Pseudotyped lentiviral vectors for retrograde gene delivery into target brain regions. Front Neuroanat 11:65CrossRefGoogle Scholar
  13. 13.
    Morgan RA, Gray D, Lomova A et al (2017) Hematopoietic stem cell gene therapy: progress and lessons learned. Cell Stem Cell 21:574–590CrossRefGoogle Scholar
  14. 14.
    Hu S, Mohan Kumar D, Sax C et al (2016) Pseudotyping of lentiviral vector with novel vesiculovirus envelope glycoproteins derived from Chandipura and Piry viruses. Virology 488:162–168CrossRefGoogle Scholar
  15. 15.
    Trobridge GD, Wu RA, Hansen M et al (2010) Cocal-pseudotyped lentiviral vectors resist inactivation by human serum and efficiently transduce primate hematopoietic repopulating cells. Mol Ther 18:725–733CrossRefGoogle Scholar
  16. 16.
    Zhou Q, Schneider IC, Edes I et al (2012) T-cell receptor gene transfer exclusively to human CD8(+) cells enhances tumor cell killing. Blood 120:4334–4342CrossRefGoogle Scholar
  17. 17.
    Segura MM, Garnier A, Durocher Y et al (2010) New protocol for lentiviral vector mass production. Methods Mol Biol 614:39–52CrossRefGoogle Scholar
  18. 18.
    Li M, Husic N, Lin Y et al (2012) Production of lentiviral vectors for transducing cells from the central nervous system. J Vis Exp 24:e4031Google Scholar
  19. 19.
    Lizee G, Aerts JL, Gonzales MI et al (2003) Real-time quantitative reverse transcriptase-polymerase chain reaction as a method for determining lentiviral vector titers and measuring transgene expression. Hum Gene Ther 14:497–507CrossRefGoogle Scholar
  20. 20.
    Sastry L, Johnson T, Hobson MJ et al (2002) Titering lentiviral vectors: comparison of DNA, RNA and marker expression methods. Gene Ther 9:1155–1162CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Medical Microbiology & ImmunologyUniversity of CaliforniaDavisUSA
  2. 2.Department of Neurology and Hope Center for Neurological DisordersWashington University School of MedicineSt LouisUSA
  3. 3.Department of Microbiology, Immunology and PathologyColorado State UniversityFort CollinsUSA

Personalised recommendations